Radioactive antibody before stem cell transplant for relapsed leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a radioactive drug, 131I-apamistamab, given before a donor stem cell transplant to help the transplant work better in people with relapsed or hard-to-treat acute myeloid leukemia (AML). The drug targets a protein on leukemia cells to deliver radiation directly to the cancer, potentially improving outcomes with fewer side effects than standard high-dose chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has come back or hasn't responded to treatment, with between 5% and 20% leukemia cells in your bone marrow.
- You are 18 years or older and are not able to receive the standard very high-dose chemotherapy conditioning (myeloablative) before transplant.
- Your leukemia cells have a specific protein called CD45 on them (this is tested in the lab).
- You have a matched sibling or unrelated donor for the stem cell transplant (8 out of 8 HLA match).
- Your kidneys, liver, and heart are working well enough, and you are generally active (able to care for yourself).
- You have not had a stem cell transplant before, and have no active infections or certain other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This trial tests a combination of two chemotherapy drugs given before a stem cell transplant to help people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The goal is to improve the success of the transplant.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.